Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

basiliximab-IR700 RM-1995

An antibody-dye conjugate composed of basiliximab, a chimeric monoclonal antibody directed against the alpha subunit of interleukin-2 receptor (IL-2R alpha, CD25 or Tac antigen), and conjugated to the light-activatable phthalocyanine dye IR700 (IRDye 700DX), with potential antineoplastic activity. Upon intravenous administration of basiliximab-IR700 RM-1995, the basiliximab moiety targets and binds to IL-2R alpha expressed on the surface of activated regulatory T lymphocytes (Tregs) in the tumor microenvironment (TME). Upon binding and localized application of 690nm nonthermal red light using the PIT690 laser system, the IR700 dye transiently becomes activated, disrupts the cell membrane and selectively kills the IL-2R alpha-expressing Tregs. This may abrogate the Tregs-mediated immunosuppressive nature of the TME and may result in systemic anti-cancer immune activation. This may activate a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells. CD25-positive Tregs inhibit antitumor immune responses and enhance tumor growth.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:basiliximab-IRDye700DX
Code name:RM 1995
RM-1995
RM1995
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search